Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus

被引:0
作者
Rieke Alten
Hans-Peter Tony
Bettina Bannert
Hubert Nüßlein
Christiane Rauch
Sean E. Connolly
Melanie Chartier
Karissa Lozenski
Roland Hackl
Adrian Forster
Peter Peichl
机构
[1] University Medicine Berlin,Department of Internal Medicine, Rheumatology, Schlosspark
[2] Universitätsklinikum Würzburg,Klinik
[3] Rheumatologische Universitätsklinik,Medizinische Klinik Und Poliklinik II, Rheumatologie/Klinische Immunologie
[4] Universitätsspital Basel,Medical Immunology & Fibrosis
[5] Medic-Center Nürnberg (Private Practice),Immunology and Fibrosis/Global Drug Development
[6] Bristol Myers Squibb,MESP France – Market Access
[7] Bristol Myers Squibb,Department of Internal Medicine
[8] Bristol Myers Squibb,undefined
[9] Immuno-Oncology,undefined
[10] Bristol Myers Squibb,undefined
[11] Department of Rheumatology,undefined
[12] Schulthess Klinik,undefined
[13] Evangelical Hospital,undefined
来源
Clinical Rheumatology | 2023年 / 42卷
关键词
Abatacept; bDMARD; Clinical response; Retention; Rheumatoid arthritis; Serostatus;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2321 / 2334
页数:13
相关论文
共 408 条
[21]  
Funovits J(2020)Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis Tohoku J Exp Med 86 753-1352
[22]  
Felson DT(2019)Two-year abatacept retention rate in clinical practice in the French ACTION cohort Joint Bone Spine 170 132-3059
[23]  
Bingham CO(2020)Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study Wien Med Wochenschr 5 3-undefined
[24]  
Birnbaum NS(2021)Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study BMC Rheumatol 3 e000538-undefined
[25]  
Burmester GR(2017)Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study RMD Open 34 489-undefined
[26]  
Bykerk VP(2016)Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study Clin Exp Rheumatol 68 1346-undefined
[27]  
Cohen MD(2016)Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European registry analysis Arthritis Rheumatol 22 64-undefined
[28]  
Combe B(2020)Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells Arthritis Res Ther 38 3049-undefined
[29]  
Costenbader KH(2019)Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries Clin Rheumatol undefined undefined-undefined
[30]  
Dougados M(undefined)undefined undefined undefined undefined-undefined